Macrophages are innate immune cells that, when recruited to tumors, can promote tumor progression. Macrophage activity and phenotype can be influenced by molecules secreted by
A team of cancer researchers has identified a pair of enzymes that they say could serve as therapeutic targets whose inhibition would block the growth
MicroRNAs (miRNAs) regulate gene expression by inducing mRNA decay. But miRNAs can be regulated through other RNAs and DNA that bind and sequester them without
Metastasizing cancer cells travel through the lymphatic vasculature, but it’s not clear what role the formation of lymph vessels, called lymphangiogenesis, plays in cancer progression.
We describe the development of a nanoparticle platform that overcomes the immunosuppressive tumor microenvironment. These nanoparticles are coated with two different antibodies that simultaneously block
Scientists at Dartmouth’s Norris Cotton Cancer Center have found that resident memory T cells can play an important role in preventing melanoma. The work began
Adoptive cell therapy (ACT) has shown promise for a variety of cancer subtypes, with clinical trial data showing that up to 40% of Stage IV
Highlights •Melanoma tumors with loss of IFN-γ signaling lack response to ipilimumab •Cell lines that are resistant to IFN-γ in vitro have defective IFN-γ pathway •Mice
By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost
Antioxidants decrease the levels of DNA-damaging, cancer-causing reactive oxygen species (ROS) that are formed during normal metabolism. Yet clinical trials that evaluated the health benefits
By now, it has become readily apparent to most that protracted exposure to the sun and UV rays leads to increased incidences of skin cancer,
The list of coffee’s beneficial attributes has grown. Over the past several years the protective effects of consuming the dark brew has been shown for
Merck & Co. has won FDA approval for its melanoma immunotherapy Keytruda (pembrolizumab), formerly called MK-3475—the first programmed death receptor-1 (PD-1) inhibitor to be allowed for use as a
Merck & Co. has won FDA approval for its melanoma immunotherapy Keytruda (pembrolizumab), formerly called MK-3475—the first programmed death receptor-1 (PD-1) inhibitor to be allowed for use as a
Created by ePubSystems. Contact Us for similar site for your university or institute.